{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-109893","form_type":"8-K","ticker":"PTPI","cik":"0001815903","company_name":"Petros Pharmaceuticals, Inc.","filed_at":"2024-10-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.788420+00:00","generated_at":"2026-05-30T12:48:47.044090+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Petros Pharma reduces President Boctor's base salary to $280K, sets Dec 31 termination","bullets":["Base salary cut from $350K to $280K effective Oct 16, 2024.","Employment termination date set to Dec 31, 2024; at-will status continues.","Boctor now permitted to engage in other consulting/employment activities if no conflict.","Amendment approved by Director Josh Silverman."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-109893","json":"https://secwatch.observer/filing/0001104659-24-109893.json","markdown":"https://secwatch.observer/filing/0001104659-24-109893.md","text":"https://secwatch.observer/filing/0001104659-24-109893.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815903/000110465924109893/0001104659-24-109893-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815903/000110465924109893/tm2426328d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T12:48:47.044090+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}